Tolcapone - Corino Therapeutics/SOM Biotech

Drug Profile

Tolcapone - Corino Therapeutics/SOM Biotech

Alternative Names: CRX-1008; SOM 0226

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SOM Biotech
  • Developer SOM Biotech; Vall d-Hebron Research Institute
  • Class Antiparkinsonians; Benzophenones; Nitrophenols; Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors; Prealbumin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity No
  • Available For Licensing Yes - Amyloid polyneuropathy

Highest Development Phases

  • Phase II Amyloid polyneuropathy

Most Recent Events

  • 19 Jul 2018 Corino Therapeutics plans an early phase I trial for Amyloidosis in USA (NCT03591757)
  • 22 May 2017 Tolcapone licensed to Corino Therapeutics worldwide
  • 31 Mar 2017 Phase-II development for Amyloid polyneuropathy is ongoing in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top